MedWatch

Fujifilm loses contract partner Novavax

A lack of demand for Novavax’s Covid-19 vaccines is behind the decision to terminate a manufacturing deal with CDMO Fujifilm, which is set to receive USD 185m as consolation.

Fujifilm Diosynth Biotechnologies will no longer produce Covid-19 vaccines for Novavax in the US | Photo: Fujifilm Diosynth Biotechnologies/PR

Novavax’s Covid-19 vaccines are selling at a snail’s pace in the US, which is why the company has decided to withdraw from a manufacturing deal with contract manufacturer, or CDMO, Fujifilm Diosynth Biotechnologies, industry media Fierce Pharma reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs